Kaplan Fox Reminds Investors of Class Action Lawsuit Against Applied Therapeutics, Inc. (APLT) and claimant filing deadline February 18, 2025. By Investing.com
NEW YORK – January 13, 2025 (NEWMEDIAWIRE) – Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Applied Therapeutics (NASDAQ:), Inc . (Applied Therapeutics or the Companies) (NASDAQ: APLT ) on behalf of investors who purchased or otherwise acquired securities of Applied Therapeutics between January 3, 2024 and December 2, 2024 (the Class Period).
CLICK HERE TO JOIN THE CASE
If you are an investor in Applied Therapeutics and have suffered losses, you can CLICK HERE to contact us. You can also contact Kaplan Fox by emailing jcampisi@kaplanfox.com or calling (212) 329-8571.
DEADLINE REMINDER: If you are a member of the proposed class, you may move the court no later than February 18, 2025 to be the lead plaintiff for the proposed class. If you have losses, we encourage you to contact us to learn more about the Attorney General process. You do not need to seek to become a lead prosecutor to participate in a potential recovery.
According to the complaint, on November 27, 2024, the company disclosed that the US Food and Drug Administration (FDA) had issued a complete response letter (CRL) for its new drug application for goverestat, AT-007-1002, for the treatment of galactosemia classica (NDA). . The company’s press release states that the CRL indicates[d] that the FDA has completed its review of the application and determined that it is unable to approve the NDA in its current form, citing deficiencies in clinical application.
Following this news, on November 29, 2024, Applied Therapeutics stock fell $6.54 per share, more than 76%, to close at $2.03 per share on heavy trading volume.
Then, on December 2, 2024, after the market closed, the Company disclosed in a Form 8-K that following the issuance of the CRL, the Company received a warning letter limited to study AT-007-1002 and that the warning letter identified issues related to the electronic data collection and a dosing error in the dose-escalation phase of the study that resulted in slightly lower than targeted levels in a limited number of patients, which was rectified before reaching the maintenance dose. According to the complaint, Applied Therapeutics’ stock price fell from a closing market price of $1.75 per share on December 2, 2024 to $1.29 per share on December 5, 2024.
WHY CONTACT KAPLAN FOX – Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and results clients demand. Through litigating cases at the federal and state levels, Kaplan Fox has successfully shaped the law by making many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you can visit our website at www.kaplanfox.com.
This press release may be considered solicitor advertising in some jurisdictions under applicable law and ethics rules.
If you have any questions about this Notice, your rights or interests, please contact:
CONTACT:
Jeffrey P. Campisi
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th floor
New York, New York 10022
(212) 329-8571
campisi@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com
See the original release at www.newmediawire.com
Copyright 2025 JCN Newswire. All rights reserved.
